Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer.

Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH.

Cancer Res. 2018 May 29. pii: canres.3821.2017. doi: 10.1158/0008-5472.CAN-17-3821. [Epub ahead of print]

PMID:
29844122
2.

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

Patel SA, Minn AJ.

Immunity. 2018 Mar 20;48(3):417-433. doi: 10.1016/j.immuni.2018.03.007. Review.

PMID:
29562193
3.

Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use.

Benci JL, Minn AJ, Vachani CC, Bach C, Arnold-Korzeniowski K, Hampshire MK, Metz JM, Hill-Kayser CE.

Cancer. 2018 Jan 1;124(1):183-191. doi: 10.1002/cncr.30985. Epub 2017 Sep 8.

PMID:
28885696
4.

Mitotic progression following DNA damage enables pattern recognition within micronuclei.

Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA.

Nature. 2017 Aug 24;548(7668):466-470. doi: 10.1038/nature23470. Epub 2017 Jul 31.

5.

Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer.

Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, Benci JL, DeMichele AM, Tchou J, Marcotrigiano J, Minn AJ.

Cell. 2017 Jul 13;170(2):352-366.e13. doi: 10.1016/j.cell.2017.06.031.

6.

Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.

Sivanand S, Rhoades S, Jiang Q, Lee JV, Benci J, Zhang J, Yuan S, Viney I, Zhao S, Carrer A, Bennett MJ, Minn AJ, Weljie AM, Greenberg RA, Wellen KE.

Mol Cell. 2017 Jul 20;67(2):252-265.e6. doi: 10.1016/j.molcel.2017.06.008. Epub 2017 Jul 6.

7.

Radiation and Immune Checkpoint Blockade: From Bench to Clinic.

Shabason JE, Minn AJ.

Semin Radiat Oncol. 2017 Jul;27(3):289-298. doi: 10.1016/j.semradonc.2017.03.002. Epub 2017 Mar 16. Review.

PMID:
28577836
8.

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ.

Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.

9.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MCU.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014. doi: 10.1038/npjbcancer.2015.14.

10.

Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing.

Jiang Y, Qiu Y, Minn AJ, Zhang NR.

Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5528-37. doi: 10.1073/pnas.1522203113. Epub 2016 Aug 29.

11.

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling.

Minn AJ, Wherry EJ.

Cell. 2016 Apr 7;165(2):272-5. doi: 10.1016/j.cell.2016.03.031. Review.

12.

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2016 Apr;156(2):405-6. doi: 10.1007/s10549-016-3752-9.

13.

Getting Tumor Dendritic Cells to Engage the Dead.

Cucolo L, Minn AJ.

Cancer Cell. 2015 Dec 14;28(6):685-687. doi: 10.1016/j.ccell.2015.11.009.

14.

Interferons and the Immunogenic Effects of Cancer Therapy.

Minn AJ.

Trends Immunol. 2015 Nov;36(11):725-737. doi: 10.1016/j.it.2015.09.007. Review.

15.

Tumour exosome integrins determine organotropic metastasis.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D.

Nature. 2015 Nov 19;527(7578):329-35. doi: 10.1038/nature15756. Epub 2015 Oct 28.

16.

Linking primary and metastatic tumour re-initiation.

Nabet BY, Minn AJ.

Nat Cell Biol. 2015 May;17(5):542-3. doi: 10.1038/ncb3173.

PMID:
25925584
17.

Awakening the immune system with radiation: Optimal dose and fractionation.

Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A.

Cancer Lett. 2015 Nov 28;368(2):185-90. doi: 10.1016/j.canlet.2015.03.024. Epub 2015 Mar 20. Review.

PMID:
25799953
18.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

19.

Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.

Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ, Jonkers J, Slingerland J, Minn AJ.

Cell. 2014 Oct 23;159(3):499-513. doi: 10.1016/j.cell.2014.09.051.

20.

MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma.

Mucaj V, Lee SS, Skuli N, Giannoukos DN, Qiu B, Eisinger-Mathason TS, Nakazawa MS, Shay JE, Gopal PP, Venneti S, Lal P, Minn AJ, Simon MC, Mathew LK.

Oncogene. 2015 Apr 23;34(17):2204-14. doi: 10.1038/onc.2014.168. Epub 2014 Jun 23.

21.

miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.

Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan P, Imtiyaz HZ, Zhang Z, Davuluri RV, Rao S, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Minn AJ, Simon MC.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):291-6. doi: 10.1073/pnas.1314341111. Epub 2013 Dec 24.

22.

The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.

Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A.

Blood. 2013 Dec 19;122(26):4220-9. doi: 10.1182/blood-2012-12-473090. Epub 2013 Oct 29.

23.

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM.

EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27.

24.

TAp73 enhances the pentose phosphate pathway and supports cell proliferation.

Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M, Yang X.

Nat Cell Biol. 2013 Aug;15(8):991-1000. doi: 10.1038/ncb2789. Epub 2013 Jun 30.

25.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(2):405-6.

26.

Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma.

Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A.

RNA. 2013 Feb;19(2):177-90. doi: 10.1261/rna.036467.112. Epub 2012 Dec 18.

27.

Identification of novel metastasis suppressor signaling pathways for breast cancer.

Minn AJ, Bevilacqua E, Yun J, Rosner MR.

Cell Cycle. 2012 Jul 1;11(13):2452-7. doi: 10.4161/cc.20624. Epub 2012 Jul 1. Review.

28.

Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer.

Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, Liang H, Li WH, Ishwaran H, Minn AJ, Rosner MR.

EMBO J. 2011 Aug 26;30(21):4500-14. doi: 10.1038/emboj.2011.312.

29.

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98.

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB.

J Immunol. 2010 Oct 1;185(7):3788-99. No abstract available.

30.

Genes that mediate breast cancer metastasis to the brain.

Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J.

Nature. 2009 Jun 18;459(7249):1005-9. doi: 10.1038/nature08021. Epub 2009 May 6.

31.

Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.

Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR.

EMBO J. 2009 Feb 18;28(4):347-58. doi: 10.1038/emboj.2008.294. Epub 2009 Jan 15.

32.

An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer.

Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ.

Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5. doi: 10.1073/pnas.0809242105. Epub 2008 Nov 10.

33.

RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.

Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop DK.

Cancer Res. 2007 Oct 15;67(20):9658-65.

34.

Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells.

Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, Mauceri HJ, Roizman B, Weichselbaum RR.

Cancer Res. 2007 Oct 1;67(19):9214-20.

35.

Lung metastasis genes couple breast tumor size and metastatic spread.

Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massagué J.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6740-5. Epub 2007 Apr 9.

36.

Identifying site-specific metastasis genes and functions.

Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, Olshen AB, Gerald WL, Massagué J.

Cold Spring Harb Symp Quant Biol. 2005;70:149-58.

PMID:
16869748
37.

Genes that mediate breast cancer metastasis to lung.

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J.

Nature. 2005 Jul 28;436(7050):518-24.

38.
39.

Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.

Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massagué J.

J Clin Invest. 2005 Jan;115(1):44-55.

40.

Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms.

Minn AJ, Kettlun CS, Liang H, Kelekar A, Vander Heiden MG, Chang BS, Fesik SW, Fill M, Thompson CB.

EMBO J. 1999 Feb 1;18(3):632-43.

41.

Recent progress on the regulation of apoptosis by Bcl-2 family members.

Minn AJ, Swain RE, Ma A, Thompson CB.

Adv Immunol. 1998;70:245-79. Review. No abstract available.

PMID:
9755339
42.

Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2.

Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB.

EMBO J. 1997 Mar 3;16(5):968-77.

43.

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.

Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW.

Science. 1997 Feb 14;275(5302):983-6.

44.

Bcl-x(L) forms an ion channel in synthetic lipid membranes.

Minn AJ, Vélez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB.

Nature. 1997 Jan 23;385(6614):353-7.

PMID:
9002522
45.
46.

Bcl-x(S) anatagonizes the protective effects of Bcl-x(L).

Minn AJ, Boise LH, Thompson CB.

J Biol Chem. 1996 Mar 15;271(11):6306-12.

47.

A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells.

Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, González-García M, Doedens M, Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Núñez G.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11024-8.

48.

Receptors that regulate T-cell susceptibility to apoptotic cell death.

Boise LH, Minn AJ, Thompson CB.

Ann N Y Acad Sci. 1995 Sep 7;766:70-80. Review.

PMID:
7486701
49.

Expression of bcl-xL can confer a multidrug resistance phenotype.

Minn AJ, Rudin CM, Boise LH, Thompson CB.

Blood. 1995 Sep 1;86(5):1903-10.

50.

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB.

Immunity. 1995 Jul;3(1):87-98.

Supplemental Content

Support Center